These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37423117)

  • 1. Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells.
    Wang J; Zeng L; Wu N; Liang Y; Jin J; Fan M; Lai X; Chen ZS; Pan Y; Zeng F; Deng F
    Drug Resist Updat; 2023 Sep; 70():100985. PubMed ID: 37423117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knocking down SOX2 overcomes the resistance of prostate cancer to castration via notch signaling.
    Du Z; Chen X; Zhu P; Lv Q; Yong J; Gu J
    Mol Biol Rep; 2023 Nov; 50(11):9007-9017. PubMed ID: 37716921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.
    Nguyen HG; Yang JC; Kung HJ; Shi XB; Tilki D; Lara PN; DeVere White RW; Gao AC; Evans CP
    Oncogene; 2014 Sep; 33(36):4521-30. PubMed ID: 24662833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients.
    Joulia ML; Carton E; Jouinot A; Allard M; Huillard O; Khoudour N; Peyromaure M; Zerbib M; Schoemann AT; Vidal M; Goldwasser F; Alexandre J; Blanchet B
    Clin Genitourin Cancer; 2020 Apr; 18(2):155-160. PubMed ID: 31630979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX8 Knockdown Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer by Inhibiting the Notch Signaling Pathway.
    Du Z; Chen X; Zhu P; Sun W; Lv Q; Cheng S; Yang X; Yu X
    Biomed Res Int; 2022; 2022():9235837. PubMed ID: 36246971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC).
    Kong Y; Cheng L; Mao F; Zhang Z; Zhang Y; Farah E; Bosler J; Bai Y; Ahmad N; Kuang S; Li L; Liu X
    J Biol Chem; 2018 Sep; 293(37):14328-14341. PubMed ID: 30089652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PHGDH Inhibits Ferroptosis and Promotes Malignant Progression by Upregulating SLC7A11 in Bladder Cancer.
    Shen L; Zhang J; Zheng Z; Yang F; Liu S; Wu Y; Chen Y; Xu T; Mao S; Yan Y; Li W; Zhang W; Yao X
    Int J Biol Sci; 2022; 18(14):5459-5474. PubMed ID: 36147463
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
    Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma.
    Wu X; Xia J; Zhang J; Zhu Y; Wu Y; Guo J; Chen S; Lei Q; Meng B; Kuang C; Feng X; He Y; Shen Y; Li X; Qiu L; Li G; Zhou W
    Br J Haematol; 2020 Jul; 190(1):52-66. PubMed ID: 32037523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients.
    Luo Y; Li Q; Yang X; Wei D; Feng B; Li M; Han Y; Zhao J; Lin Y; Li Q; Hou Z; Zhuang H; Jiang Y
    Dis Markers; 2021; 2021():6649579. PubMed ID: 34413914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer.
    Zhou X; Zou L; Chen W; Yang T; Luo J; Wu K; Shu F; Tan X; Yang Y; Cen S; Li C; Mao X
    Pharmacol Res; 2021 Feb; 164():105305. PubMed ID: 33197601
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Luk IS; Shrestha R; Xue H; Wang Y; Zhang F; Lin D; Haegert A; Wu R; Dong X; Collins CC; Zoubeidi A; Gleave ME; Gout PW; Wang Y
    Clin Cancer Res; 2017 Mar; 23(6):1542-1551. PubMed ID: 27663589
    [No Abstract]   [Full Text] [Related]  

  • 13. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
    Dong JK; Lei HM; Liang Q; Tang YB; Zhou Y; Wang Y; Zhang S; Li WB; Tong Y; Zhuang G; Zhang L; Chen HZ; Zhu L; Shen Y
    Theranostics; 2018; 8(7):1808-1823. PubMed ID: 29556358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
    Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
    Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer.
    Wu M; Cui J; Hou H; Li Y; Liu S; Wan L; Zhang L; Huang W; Sun G; Liu J; Jin P; He S; Liu M
    Front Pharmacol; 2022; 13():871259. PubMed ID: 35548335
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
    Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X
    Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyphyllin I induces ferroptosis in castration-resistant prostate cancer cells through the ERK/DNMT1/ACSL4 axis.
    Zou P; Chen Z; He Q; Zhuo Y
    Prostate; 2024 Jan; 84(1):64-73. PubMed ID: 37750290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles].
    Guan H; Ling ZX; Fang F; Mao LK; You ZH; Wang C; Chen SQ; Xu B; Chen M
    Zhonghua Nan Ke Xue; 2018 Feb; 24(2):116-121. PubMed ID: 30156069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PLCε knockdown overcomes drug resistance to androgen receptor antagonist in castration-resistant prostate cancer by suppressing the wnt3a/β-catenin pathway.
    Li L; Du Z; Gao Y; Tang Y; Fan Y; Sun W; Li T; Liu N; Yuan M; Fan J; Niu L; Yan J; Duan L; Wu X; Luo C
    J Cell Physiol; 2019 Sep; 234(9):15472-15486. PubMed ID: 30684266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
    Liu JS; Fang WK; Yang SM; Wu MC; Chen TJ; Chen CM; Lin TY; Liu KL; Wu CM; Chen YC; Chuu CP; Wang LY; Hsieh HP; Kung HJ; Wang WC
    J Biomed Sci; 2022 May; 29(1):29. PubMed ID: 35534851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.